- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE | - | HKEx | ||
| Fr | ZHAOKE OPHTH-B Enters Distribution and Supply Agreement with PT. ERELA for Commercialization of Cyclosporine Ophthalmic Gel in Indonesia | 1 | AASTOCKS | ||
| Fr | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ENTERING INTO DISTRIBUTION AND SUPPLY AGREEMENT WITH PT. ERELA TO COMMERCIALIZE CSA OPHTHALMIC GEL IN ... | 1 | HKEx | ||
| 27.05. | ZHAOKE OPHTH-B (06622): AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| ZHAOKE OPHTHALMOLOGY Aktie jetzt für 0€ handeln | |||||
| 15.05. | ZHAOKE OPHTH-B (06622): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 15, 2026 | 1 | HKEx | ||
| 30.04. | ZHAOKE OPHTH-B (06622): CONTINUING CONNECTED TRANSACTIONS IN RELATION TO RENEWAL OF MASTER CMO SERVICE AGREEMENT | - | HKEx | ||
| 23.04. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM | - | HKEx | ||
| 23.04. | ZHAOKE OPHTH-B (06622): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM | 2 | HKEx | ||
| 23.04. | ZHAOKE OPHTH-B (06622): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, MAY 15, 2026 | 1 | HKEx | ||
| 23.04. | ZHAOKE OPHTH-B (06622): (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES; (2) PROPOSED RE-ELECTION OF THE RETIRING ... | 1 | HKEx | ||
| 23.04. | ZHAOKE OPHTH-B (06622): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | ZHAOKE OPHTH-B (06622): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | 2 | HKEx | ||
| 23.04. | ZHAOKE OPHTH-B (06622): 2025 ANNUAL REPORT | - | HKEx | ||
| 15.04. | ZHAOKE OPHTH-B (06622): PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 25.03. | ZHAOKE OPHTH-B (06622): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 11.03. | ZHAOKE OPHTH-B (06622): NOTICE OF BOARD MEETING | 1 | HKEx | ||
| 29.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ZHAOKE OPHTHALMOLOGY'S PARTNER TENPOINT THERAPEUTICS, LTD. RECEIVES FDA APPROVAL FOR BRIMOCHOL PF IN ... | - | HKEx | ||
| 26.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - ADVANCING COMMERCIALIZATION OF BRIMOCHOL PF FOR PRESBYOPIA IN SINGAPORE AND VIETNAM THROUGH PARTNERSHIPS ... | 1 | HKEx | ||
| 13.01. | ZHAOKE OPHTH-B (06622): VOLUNTARY ANNOUNCEMENT - REGISTRATION APPLICATION FOR ATROPINE SULFATE EYE DROPS ACCEPTED FOR EVALUATION BY AUSTRALI'S THERAPEUTIC ... | 1 | HKEx |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 31,740 | -0,02 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Feedback aus Gesprächen mit etlichen US-Laborexperten deute darauf hin, dass... ► Artikel lesen | |
| TANGO THERAPEUTICS | 30,340 | -1,91 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| NURIX THERAPEUTICS | 15,075 | -3,61 % | Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein | DJ Roche geht 2,3-Milliarden-Dollar-Deal mit Nurix für Blutkrebsmittel ein
Von Nina Kienle
DOW JONES--Roche hat mit dem US-Biotechunternehmen Nurix Therapeutics eine exklusive Lizenz- und Kooperationsvereinbarung... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,040 | -0,50 % | All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy | ||
| ERASCA | 12,495 | -2,91 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,130 | -0,10 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 39,690 | +5,08 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity | ||
| BIONTECH | 73,95 | -0,27 % | Neue CAR-T-Erfolge bei Autoimmunerkrankungen: Warum Lösungen für Zelltherapien vor dem nächsten Wachstumsschub stehen könnten | ||
| MINERALYS THERAPEUTICS | 23,200 | +3,11 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,135 | -5,57 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| CG ONCOLOGY | 54,35 | -0,09 % | CG Oncology, Inc. - 8-K, Current Report | ||
| EVOTEC | 4,750 | 0,00 % | EQS-News: Evotec SE: Evotec ernennt Rui Wang zum Head of Global In Silico & AI | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Rui Wang zum Head of Global In Silico & AI
02.06.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,140 | -2,15 % | Beam Therapeutics Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 245,13 | -3,21 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| IMMUNOVANT | 30,470 | -1,07 % | H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data |
ZHAOKE OPHTHALMOLOGY LTD gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +10,24 % bei einem Aktienkurs von 0,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZHAOKE OPHTHALMOLOGY LTD finden Sie auf Wallstreet Online.